Advanced glycation end-products in diabetic nephropathy

Nephrology Dialysis Transplantation

Volumn 11, Issue SUPPL. 5, 1996, Pages 91-94

  Sugiyama, S ^a   Miyata, T ^b   Horie, K ^b   Iida, Y ^b   Tsuyuki, M ^a   Tanaka, H ^a   Maeda, K ^b  

^a CHUKYO HOSPITAL   (Japan)

^b NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Advanced glycation end products; Diabetes mellitus; End stage renal failure; Nephropathy

Indexed keywords

GLUCOSE; GLYCOSYLATED PROTEIN; MATRIX PROTEIN; SCHIFF BASE;

AGED; BLOOD LEVEL; CASE REPORT; CONFERENCE PAPER; DIABETES MELLITUS; DIABETIC NEPHROPATHY; GLYCATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; IMMUNOGLOBULIN A NEPHROPATHY; IMMUNOHISTOCHEMISTRY; KIDNEY FUNCTION; MALE; MESANGIUM CELL; PRIORITY JOURNAL;

EID: 0030512148     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/11.supp5.91     Document Type: Conference Paper

References (25)

1. The Diabetes Control and Complications Research Group. Effect of intensive therapy on the development and progression of diabetic nephropathy in the diabetes control and complications trial. Kidney Int 1995; 47: 1703-1720
2. Bangstad HJ, Østerby R, Dahl-Jørgensen K, Berg KJ, Hartmann A, Hanssen KF. Improvement of blood glucose control in IDDM patients retards the progression of morphological changes in early diabetic nephropathy. Diabetologia 1994; 37: 483-490
3. Brownlee M, Cerami A, Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 1988; 318: 1315-1321
4. Monnier VM, Vishwanath V, Frank KE, Elmets CA, Dauchot P, Kohn RR. Relation between complications of type I diabetes mellitus and collagen-linked fluorescence. N Engl J Med 1986; 314: 403-408
5. Sell DR, Monnier VM. Structure elucidation of a senescence cross-link from human extracellular matrix. J Biol Chem 1989; 264: 21597-21602
6. Dyer DG, Dunn JA, Thorpe SR et al. Accumulation of Maillard reaction products in skin collagen in diabetes and aging. J Clin Invest 1993; 91: 2463-2469
7. Monnier VM, Sell DR, Nagaraj RH et al. Maillard reaction-mediated molecular damage to extracellular matrix and other tissue proteins in diabetes, aging, and uremia. Diabetes 1992; 41: 36-41
8. Odetti P, Forgarty J, Sell DR, Monnier VM. Chromatographic quantitation of plasma and erythrocyte pentosidine in diabetic and uremic subjects. Diabetes 1992; 41: 153-159
9. Sell DR, Lapolla A, Odetti P, Forgarty J, Monnier VM. Pentosidine formation in skin correlates with severity of complication in individuals with long standing IDDM. Diabetes 1992; 41: 1286-1292
10. McCance DR, Dyer DG, Dunn JA et al. Maillard reaction products and their relation to complications in insulin-dependent diabetes mellitus. J Clin Invest 1993; 91: 2470-2478
11. Sell DR, Carlson EC, Monnier VM. Differential effects of type 2 (non-insulin-dependent) diabetes mellitus on pentosidine formation in skin and glomerular basement membrane. Diabetologia 1993; 36: 936-941
12. Steffes MW, Østerby R, Chavers B, Mauer SM. Mesangial expansion as a central mechanism for loss of kidney function in diabetic patients. Diabetes 1989; 38: 1077-1081
13. Skolnik EY, Yang Z, Makita Z, Radoff S, Kirstein M, Vlassara H. Human and rat mesangial cell receptors for glucose-modified proteins: potential role in kidney tissue remodelling and diabetic nephropathy. J Exp Med 1991; 174: 931-939
14. Makino H, Shikata K, Hironaka K et al. Ultrastructure of nonenzymatically glycated mesangial matrix in diabetic nephropathy. Kidney Int 1995; 48: 517-526
15. Miyata S, Monnier VM. Immunohistochemical detection of advanced glycosylation end products in diabetic tissues using monoclonal antibody to pyrraline. J Clin Invest 1992; 89: 1102-1112
16. Miyata T, Inagi R, Iida Y et al. Involvement of β2-microglobulin modified with advanced glycation end products in the pathogenesis of hemodialysis-associated amyloidosis: induction of human monocyte chemotaxis and macrophage secretion of tumor necrosis factor-α and interleukin 1. J Clin Invest 1994; 93: 521-528
17. Iida Y, Miyata T, Inagi R, Sugiyama S, Maeda K. β2-Microglobulin modified with advanced glycation end products induces interleukin-6 from human macrophages: role in the pathogenesis of hemodialysis-associated amyloidosis. Biochem Biophys Res Commun 1994; 201: 1235-1241
18. Miyata T, Iida Y, Ueda Y et al. Monocyte/macrophage response to β2-microglobulin modified with advanced glycation end products. Kidney Int 1996; 49: 538-550
19. Neeper M, Schmidt AM, Brett J et al. Cloning and expression of RAGE: a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem 1992; 267: 14998-15006
20. Iida Y, Miyata T, Maeda K, Hori O, Stern D, Schmidt AM. Monocyte/macrophage interaction of nonenzymatically glycated β2-microglobulin is mediated by the receptor for advanced glycation end products: role in the pathogenesis of dialysis-related amyloidosis. (Abstract.) J Am Soc Nephrol 1995; 6: 536
21. Baynes JW. Perspectives in diabetes: role of oxidative stress in development of complications in diabetes. Diabetes 1991; 40: 405-412
22. Yan SD, Schmidt AM, Anderson GM et al. Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J Biol Chem 1994; 269: 9889-9897
23. Doi T, Vlassara H, Kirstein M, Yamada Y, Striker GE, Striker LJ. Receptor-specific increase in extracellular matrix production in mouse mesangial cells by advanced glycosylation end products is mediated via platelet-derived growth factor. Proc Natl Acad Sci USA 1992; 89: 2873-2877
24. Liparota TS, Cooper M, Papazogloti D et al. Retardation by aminoguanidine of development of albuminuria, mesangial expansion, and tissue fluorescence in streptozocin-induced diabetic rat. Diabetes 1991; 40: 1328-1334
25. Cohen MP Hud E, Wu VY. Amelioration of diabetic nephropathy by treatment with monoclonal antibodies against glycated albumin. Kidney Int 1994; 45: 1673-1679